Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Neoplasms × tislelizumab × Clear all

Phase

Phase 1/2 2 Phase 4 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 25 Carcinoma, Hepatocellular 22 Colorectal Neoplasms 16 Stomach Neoplasms 13 Esophageal Squamous Cell Carcinoma 13 Esophageal Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 10 Lung Neoplasms 8 Head and Neck Neoplasms 8 Cholangiocarcinoma 7 Uterine Cervical Neoplasms 6 Triple Negative Breast Neoplasms 6 Small Cell Lung Carcinoma 6 Nasopharyngeal Carcinoma 6 Rectal Neoplasms 5 Recurrence 4 Pancreatic Neoplasms 4 Locally Advanced Rectal Cancer 4 Hodgkin Disease 4 Colonic Neoplasms 4 Neoplasms 3 NSCLC 3 Lymphoma, Extranodal NK-T-Cell 3 Glioblastoma 3 Adenocarcinoma 3 Urinary Bladder Neoplasms 2 Ovarian Neoplasms 2 Neoplasm, Residual 2 Melanoma 2 Lymphoma, Follicular 2

Interventions

Trastuzumab 266 Paclitaxel 228 Cyclophosphamide 223 Docetaxel 210 Capecitabine 162 Letrozole 143 Carboplatin 142 Fulvestrant 132 Doxorubicin 130 Bevacizumab 111 Anastrozole 92 Tamoxifen 88 Vinorelbine 83 exemestane 78 Gemcitabine 78 Epirubicin 78 Lapatinib 73 pertuzumab 71 Radiotherapy 65 Albumin-Bound Paclitaxel 65 pembrolizumab 63 palbociclib 57 eribulin 52 Cisplatin 50 130-nm albumin-bound paclitaxel 49 Everolimus 44 Taxes 39 Neoadjuvant Therapy 38 Goserelin 37 pyrotinib 34

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04734262 2023-11-18

SPARK

Fudan University

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡